1. Home
  2. EKSO vs XLO Comparison

EKSO vs XLO Comparison

Compare EKSO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ekso Bionics Holdings Inc.

EKSO

Ekso Bionics Holdings Inc.

HOLD

Current Price

$10.40

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$7.25

Market Cap

39.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EKSO
XLO
Founded
2005
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
39.4M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
EKSO
XLO
Price
$10.40
$7.25
Analyst Decision
Buy
Buy
Analyst Count
2
1
Target Price
$9.50
$28.00
AVG Volume (30 Days)
88.5K
315.0K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
41.76
60.79
EPS
N/A
N/A
Revenue
N/A
$6,344,000.00
Revenue This Year
$81.23
$626.78
Revenue Next Year
$7.29
$79.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.46
52 Week High
$13.50
$8.09

Technical Indicators

Market Signals
Indicator
EKSO
XLO
Relative Strength Index (RSI) 47.11 91.60
Support Level $9.18 $0.63
Resistance Level $10.76 N/A
Average True Range (ATR) 1.01 0.29
MACD -0.22 0.83
Stochastic Oscillator 12.79 95.81

Price Performance

Historical Comparison
EKSO
XLO

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: